Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

The Lancet Oncology 2026

View at publisher
Authors: Shankar Siva, Muhammad Ali, Nicholas Hardcastle, Tomas Kron, Braden Higgs, Farshad Foroudi, Jeremy Ruben, Sree Appu, Jarad Martin, Swetha Sridharan, Rebecca Montgomery, Ryan Davey
+11 more Charles Lin, Mark Shaw, Sarat Chander, Mark Sidhom, Ben G L Vanneste, Declan G Murphy, Nathan Lawrentschuk, David Pryor, Simon Wood, Daniel Moon, Mathias Bressel
DOI: 10.1016/s1470-2045(26)00170-1
Cited by: 5
References: 18

Fields of Study & Subjects

Renal cell carcinoma treatment Hepatocellular Carcinoma Treatment and Prognosis Management of metastatic bone disease

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
6
Pages
721–728
Publication date
17 May 2026
Language
EN